IDEAS home Printed from https://ideas.repec.org/p/cbo/wpaper/55011.html
   My bibliography  Save this paper

Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid: An In-Depth Analysis: Working Paper 2019-02

Author

Listed:
  • Anna Anderson-Cook
  • Jared Maeda
  • Lyle Nelson

Abstract

In this working paper, the Congressional Budget Office examines the prices paid for specialty drugs and spending on those drugs in Medicare Part D and Medicaid from 2010 to 2015. Specialty drugs treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or monitoring of patients. The retail prices paid to pharmacies for brand-name specialty drugs are similar in Medicare Part D and Medicaid, but net prices are much higher in Medicare Part D because rebates from manufacturers are substantially lower than in Medicaid. In 2015, the

Suggested Citation

  • Anna Anderson-Cook & Jared Maeda & Lyle Nelson, 2019. "Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid: An In-Depth Analysis: Working Paper 2019-02," Working Papers 55011, Congressional Budget Office.
    • Handle: RePEc:cbo:wpaper:55011
    as

    Download full text from publisher

    File URL: https://www.cbo.gov/system/files/2019-03/55011-Specialty_Drugs_WP.pdf
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Paweł Żelewski & Michał Wojna & Katarzyna Sygit & Elżbieta Cipora & Izabela Gąska & Mateusz Niemiec & Mateusz Kaczmarski & Tomasz Banaś & Beata Karakiewicz & Artur Kotwas & Paulina Zabielska & Olga Pa, 2022. "Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union," IJERPH, MDPI, vol. 19(19), pages 1-17, September.
    2. Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.

    More about this item

    JEL classification:

    • I10 - Health, Education, and Welfare - - Health - - - General
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I13 - Health, Education, and Welfare - - Health - - - Health Insurance, Public and Private
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cbo:wpaper:55011. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/cbogvus.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.